01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents

Jennifer Yu, MBBSa,b; Usman Baber, MDb; Ioannis Mastoris, MDb; George Dangas, MD, PhDb; Samantha Sartori, PhDb; Philippe Gabriel Steg, MDc; David J. Cohen, MD, MScd; Gennaro Giustino, MDb; Jaya Chandrasekhar, MBBSb; Cono Ariti, MSce; Bernhard Witzenbichler, MDf; Timothy D. Henry, MDg; Annapoorna S. Kini, MDb; Mitchell W. Krucoff, MDh; C. Michael Gibson, MDi; Alaide Chieffo, MDj; David J. Moliterno, MDk; Antonio Colombo, MDj; Stuart Pocock, PhDe; Roxana Mehran, MDb

Objectives: The aim of this study was to compare the incidence and impact of cessation of dual-antiplatelet therapy (DAPT) in women and men treated with percutaneous coronary intervention.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Duration of Triple Antithrombotic Therapy and Outcomes Among Patients Undergoing Percutaneous Coronary Intervention

Konstantinos C. Koskinas, MD, MSca; Lorenz Räber, MD, PhDa; Thomas Zanchin, MDa; Thomas Pilgrim, MDa; Stefan Stortecky, MDa; Lukas Hunziker, MDa; Stefan Blöchlinger, MDa; Michael Billinger, MDa; Fabienne Gartwyl, BAa; Christina Moro, MAa; Aris Moschovitis, MDa; Peter Jüni, MDb; Dik Heg, PhDc; Stephan Windecker, MDa

Objectives: The aim of this study was to compare clinical outcomes in relation to the duration of triple antithrombotic therapy (TAT) among patients with indications for oral anticoagulation undergoing percutaneous coronary intervention (PCI).

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. “One-Stop Shop”. Safety of Combining Transcatheter Aortic Valve Replacement and Left Atrial Appendage Occlusion

Adrian Attinger-Toller, MDa; Francesco Maisano, MDa; Oliver Senn, MDb; Maurizio Taramasso, MDa; Samera Shakir, MDc; Mathias Possner, MDa; Steffen Gloekler, MDc; Stephan Windecker, MDc; Stefan Stortecky, MDc; Thomas F. Lüscher, MDa; Bernhard Meier, MDc; Fabian Nietlispach, MD, PhDa

Objectives: The aim of this study was to investigate the safety and efficacy of combining transcatheter valve replacement (TAVR) and left atrial appendage occlusion (LAAO) versus TAVR alone.

01 julio 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Prevalence and Clinical Impact of Tissue Protrusion After Stent Implantation. An ADAPT-DES Intravascular Ultrasound Substudy

Fuyu Qiu, MDa,b,c; Gary S. Mintz, MDa; Bernhard Witzenbichler, MDd; D. Christopher Metzger, MDe; Michael J. Rinaldi, MDf; Peter L. Duffy, MD, MMMg; Giora Weisz, MDa,b,h; Thomas D. Stuckey, MDi; Bruce R. Brodie, MDi; Rupa Parvataneni, MSa; Ajay J. Kirtane, MD, SMa,b; Gregg W. Stone, MDa,b; Akiko Maehara, MDa,b

Objectives: The aim of this study was to evaluate the prevalence and long-term clinical impact of tissue protrusion (TP) after stent implantation.

08 febrero 2016

CIRCULATION: CARDIOVASCULAR INTERVENTIONS. Peripheral Vascular Disease. Comparison of Long-Term Outcomes of Endovascular Management for Membranous and Segmental Inferior Vena Cava Obstruction in Patients With Primary Budd–Chiari Syndrome

Qianxin Huang, MD*, Bin Shen, MD*, Qingqiao Zhang, MD, PhD, Hao Xu, MD, Maoheng Zu, MD, Yuming Gu, MD, Ning Wei, MD, Yanfeng Cui, MD and Rui Huang, MD

Background: Endovascular management is important for the treatment of primary Budd–Chiari syndrome, which is caused by inferior vena cava (IVC) obstruction. The aims of this study were to compare long-term outcomes of endovascular management for primary Budd–Chiari syndrome patients with membranous obstruction of IVC (MOVC) and segmental obstruction of IVC (SOVC) and explore the optimal endovascular strategy for these conditions.

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents. A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries

Corrado Tamburino, MD, PhDa; Piera Capranzano, MDa; Tommaso Gori, MDb; Azeem Latib, MDc; Maciej Lesiak, MDd; Holger Nef, MDe; Giuseppe Caramanno, MDf; Christopher Naber, MDg; Julinda Mehilli, MDh; Carlo Di Mario, MDi; Manel Sabaté, MDj; Thomas Münzel, MDb; Antonio Colombo, MDc; Aleksander Araszkiewicz, MDd; Jens Wiebe, MDf; Salvatore Geraci, MDf; Christoph Jensen, MDg; Alessio Mattesini, MDi; Salvatore Brugaletta, MDj; Davide Capodanno, MD, PhDa

Objectives: The purpose of this study was to compare the 1-year outcomes of the ABSORB everolimus-eluting bioresorbable scaffold (BRS) (Abbott Vascular, Santa Clara, California) and the XIENCE everolimus-eluting stent (EES) (Abbott Vascular) in patients undergoing percutaneous coronary intervention.

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Impact of Right Atrial Pressure on Fractional Flow Reserve Measurements. Comparison of Fractional Flow Reserve and Myocardial Fractional Flow Reserve in 1,600 Coronary Stenoses

Gabor G. Toth, MDa,b; Bernard De Bruyne, MD, PhDa; Dan Rusinaru, MDa,c; Giuseppe Di Gioia, MDa,d; Jozef Bartunek, MD, PhDa; Mariano Pellicano, MDa; Marc Vanderheyden, MDa; Julien Adjedj, MDa; William Wijns, MD, PhDa; Nico H.J. Pijls, MD, PhDe,f; Emanuele Barbato, MD, PhDa,d

Objectives: This study sought to assess the impact of a wide range of mean right atrial pressure (Pra) on fractional flow reserve (FFR) measurements.

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Long-Term Outcome of Alcohol Septal Ablation for Obstructive Hypertrophic Cardiomyopathy in the Young and the Elderly

Max Liebregts, MDa; Robbert C. Steggerda, MDb; Pieter A. Vriesendorp, MDc; Hannah van Velzen, MDc; Arend F.L. Schinkel, MD, PhDc; Rik Willems, MD, PhDd; Johan van Cleemput, MD, PhDd; Maarten P. van den Berg, MD, PhDe; Michelle Michels, MD, PhDc; Jurriën M. ten Berg, MD, PhDa

Objectives: The aim of this study was to compare outcomes of alcohol septal ablation (ASA) in young and elderly patients with obstructive hypertrophic cardiomyopathy (HCM).

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Transcarotid Transcatheter Aortic Valve Replacement. Feasibility and Safety

Darren Mylotte, MDa; Arnaud Sudre, MDb; Emmanuel Teiger, MD, PhDc; Jean François Obadia, MD, PhDd; Marcus Lee, MDa; Mark Spence, MDe; Hazem Khamis, MDf; Arif Al Nooryani, MDg; Cedric Delhaye, MDb; Gilles Amr, MDb; Mohamad Koussa, MDb; Nicolas Debry, MDb; Nicolo Piazza, MD, PhDh; Thomas Modine, MD, PhDb

Objectives: The purpose of this study was to assess the feasibility and safety of transcarotid transcatheter aortic valve replacement (TAVR).

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Immediate Outcomes of Covered Stent Placement for Treatment or Prevention of Aortic Wall Injury Associated With Coarctation of the Aorta (COAST II)

Nathaniel W. Taggart, MDa; Matthew Minahan, BSb; Allison K. Cabalka, MDa; Frank Cetta, MDa; Kudret Usmani, BA, BScb; Richard E. Ringel, MDc

Objectives: This study aimed to describe the safety and short-term efficacy of the Covered Cheatham-Platinum stent (CCPS) in treating or preventing aortic wall injury (AWI) in patients with coarctation of the aorta (CoA).

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention? A Pre-Specified Analysis From the ZEUS Trial

Sara Ariotti, MDa,b; Marianna Adamo, MDb; Francesco Costa, MDb; Athanasios Patialiakas, MDc; Carlo Briguori, MD, PhDd; Attila Thury, MD, PhDe; Salvatore Colangelo, MDf; Gianluca Campo, MDg; Matteo Tebaldi, MDg; Imre Ungi, MD, PhDe; Stefano Tondi, MDh; Marco Roffi, MDi; Alberto Menozzi, MD, PhDj; Nicoletta de Cesare, MDk; Roberto Garbo, MDf; Emanuele Meliga, MDl; Luca Testa, MD, PhDm; Henrique Mesquita Gabriel, MDn; Marco Ferlini, MDo; Pascal Vranckx, MD, PhDp; Marco Valgimigli, MD, PhDa,b

Objectives: This study sought to investigate the ischemic and bleeding outcomes of patients fulfilling high bleeding risk (HBR) criteria who were randomized to zotarolimus-eluting Endeavor Sprint stent (E-ZES) or bare-metal stent (BMS) implantation followed by an abbreviated dual antiplatelet therapy (DAPT) duration for stable or unstable coronary artery disease.

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Optimal Strategy for Provisional Side Branch Intervention in Coronary Bifurcation Lesions. 3-Year Outcomes of the SMART-STRATEGY Randomized Trial

Young Bin Song, MD, PhD; Taek Kyu Park, MD; Joo-Yong Hahn, MD, PhD; Jeong Hoon Yang, MD, PhD; Jin-Ho Choi, MD, PhD; Seung-Hyuk Choi, MD, PhD; Sang Hoon Lee, MD, PhD; Hyeon-Cheol Gwon, MD, PhD

Objectives: This study compared the long-term follow-up results of conservative versus aggressive strategies for provisional side branch (SB) intervention in coronary bifurcation lesions.

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Immediate Versus Delayed Invasive Intervention for Non-STEMI Patients. The RIDDLE-NSTEMI Study

Aleksandra Milosevic, MDa,b; Zorana Vasiljevic-Pokrajcic, MD, PhDc; Dejan Milasinovic, MDa; Jelena Marinkovic, PhDb,d; Vladan Vukcevic, MD, PhDa,c; Branislav Stefanovic, MD, PhDa,b,c; Milika Asanin, MD, PhDa,b,c; Miodrag Dikic, MDa; Sanja Stankovic, PhDe; Goran Stankovic, MD, PhDa,c

Objectives: This study aimed to assess the clinical impact of immediate versus delayed invasive intervention in patients with non–ST-segment myocardial infarction (NSTEMI).

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Sex Difference in Chest Pain After Implantation of Newer Generation Coronary Drug-Eluting Stents. A Patient-Level Pooled Analysis From the TWENTE and DUTCH PEERS Trials

Marlies M. Kok, MDa; Liefke C. van der Heijden, MDa; Hanim Sen, MD, PhDa; Peter W. Danse, MD, PhDb; Marije M. Löwik, PhDa; Rutger L. Anthonio, MD, PhDc; J. (Hans) W. Louwerenburg, MDa; Frits H.A.F. de Man, MD, PhDa; Gerard C.M. Linssen, MD, PhDd; Maarten J. IJzerman, PhDe; Carine J.M. Doggen, PhDe; Angela H.E.M. Maas, MD, PhDf; Roxana Mehran, MDg; Clemens von Birgelen, MD, PhDa,e

Objectives: This study sought to assess sex differences in chest pain after percutaneous coronary intervention (PCI) with newer generation drug-eluting stents (DES).

01 marzo 2016

JACC: CARDIOVASCULAR INTERVENTIONS. Serial Multimodality Imaging and 2-Year Clinical Outcomes of the Novel DESolve Novolimus-Eluting Bioresorbable Coronary Scaffold System for the Treatment of Single De Novo Coronary Lesions

Alexandre Abizaid, MD, PhDa; Ricardo A. Costa, MD, PhDa; Joachim Schofer, MDb; John Ormiston, MBChBc; Michael Maeng, MDd; Bernhard Witzenbichler, MDe; Roberto V. Botelho, MD, PhDf; J. Ribamar Costa, Jr., MD, PhDg; Daniel Chamié, MDg; Andrea S. Abizaid, MD, PhDg; Juliana P. Castro, PhDg; Lynn Morrison, MPHh; Sara Toyloy, BSh; Vinayak Bhat, PhDh; John Yan, MSh; Stefan Verheye, MD, PhDi

Objectives: This study sought to report the late multimodality imaging and clinical outcomes of the novel poly-l-lactic-acid–based DESolve novolimus-eluting bioresorbable coronary scaffold for the treatment of de novo coronary lesions.